349609-85-4

Basic information

• Product Name: 2-pyridin-4-yl-1,3-benzoxazol-5-amine
• Synonyms: 2-pyridin-4-yl-1,3-benzoxazol-5-amine;[2-(4-pyridyl)-1,3-benzoxazol-5-yl]amine;2-(4-pyridyl)-1,3-benzoxazol-5-amine
• CAS NO: 349609-85-4
• Molecular Formula: C₁₂H₉N₃O
• Molecular Weight: 211.23
• Mol File: 349609-85-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-pyridin-4-yl-1,3-benzoxazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-pyridin-4-yl-1,3-benzoxazol-5-amine(349609-85-4)
• EPA Substance Registry System: 2-pyridin-4-yl-1,3-benzoxazol-5-amine(349609-85-4)

Safety Data

• Hazardous Substances Data: 349609-85-4(Hazardous Substances Data)

Upstream product

• 55-22-1 pyridine-4-carboxylic acid 
• 872-85-5 pyridine-4-carbaldehyde 
• 99-57-0 2-hydroxy-5-nitroaniline 
• 14254-57-0 4-(chlorocarbonyl)pyridine 
• 82341-61-5 5-nitro-2-(pyridine-4-yl)benzo[d]oxazole 

Downstream Products

• 1434517-80-2 (S)-2-(2,3-dichlorophenylamino)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-76-6 (R)-2-(2,3-dichlorophenyl)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-02-8 (S)-2-(2,3-dichlorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-77-7 2-(2,3-dichlorophenylamino)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-73-3 (R)-2-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-70-0 (S)-2-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-67-5 2-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-63-1 2-methyl-3-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 701248-69-3 C₂₁H₁₅Cl₂N₃O₃ 
• 1434517-12-0 (S)-2-(2,3-dimethoxyphenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-09-5 (S)-2-(2-chloro-3-nitrophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 1434517-06-2 (S)-2-(2-chloro-3-(trifluoromethyl)phenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propanamide 
• 833432-18-1 2-(4-chlorophenoxy)-2-methyl-N-[2-(pyridin-4-yl)-1,3-benzoxazol-5-yl]propanamide 
• 329196-55-6 C₂₀H₁₃Cl₂N₃O₃ 

Relevant articles and documents

Expanding Benzoxazole-Based Inosine 5′-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents

New drugs and molecular targets are urgently needed to address the emergence and spread of drug-resistant tuberculosis. Mycobacterium tuberculosis (Mtb) inosine 5′-monophosphate dehydrogenase 2 (MtbIMPDH2) is a promising yet controversial potential target

SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidine compounds described herein include substituted 2,4-dimethyl-N-phenylimidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.

COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS

Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.

Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5′-monophosphate dehydrogenase

Cryptosporidium parvum is an enteric protozoan parasite that has emerged as a major cause of diarrhea, malnutrition, and gastroenteritis and poses a potential bioterrorism threat. C. parvum synthesizes guanine nucleotides from host adenosine in a streamlined pathway that relies on inosine 5′-monophosphate dehydrogenase (IMPDH). We have previously identified several parasite-selective C. parvum IMPDH (CpIMPDH) inhibitors by high-throughput screening. In this paper, we report the structure-activity relationship (SAR) for a series of benzoxazole derivatives with many compounds demonstrating CpIMPDH IC50 values in the nanomolar range and >500-fold selectivity over human IMPDH (hIMPDH). Unlike previously reported CpIMPDH inhibitors, these compounds are competitive inhibitors versus NAD +. The SAR study reveals that pyridine and other small heteroaromatic substituents are required at the 2-position of the benzoxazole for potent inhibitory activity. In addition, several other SAR conclusions are highlighted with regard to the benzoxazole and the amide portion of the inhibitor, including preferred stereochemistry. An X-ray crystal structure of a representative E·IMP·inhibitor complex is also presented. Overall, the secondary amine derivative 15a demonstrated excellent CpIMPDH inhibitory activity (IC 50 = 0.5 ± 0.1 nM) and moderate stability (t1/2 = 44 min) in mouse liver microsomes. Compound 73, the racemic version of 15a, also displayed superb antiparasitic activity in a Toxoplasma gondii strain that relies on CpIMPDH (EC50 = 20 ± 20 nM), and selectivity versus a wild-type T. gondii strain (200-fold). No toxicity was observed (LD 50 > 50 μM) against a panel of four mammalian cells lines.

SUBSTITUTED PYRIMIDODIAZEPINES

The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the t